Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Article in English | IMSEAR | ID: sea-135100

ABSTRACT

With better knowledge and availability of antiretroviral treatments, the Thai National HIV Guidelines Working Group has issued treatment guidelines for children in Thailand in March 2010. The most important aspects of these new guidelines are detailed below. ART should be initiated in infants less than 12 months of age at any CD4 level regardless of symptoms and in all children at CDC clinical stage B and C or WHO clinical stages 3 and 4. For children with no or mild symptoms consider CD4-guided thresholds of CD4 <25% (children aged one to five years) or CD4 <350 cells/mm3 (children 5 years or older). The preferred first-line regimen in children aged < 3 years is AZT+3TC+NVP. For children >3 years of age the preferred regimen is AZT+3TC+EFV. If an infant has previously been exposed to NVP perinatally, use AZT+3TC+LPV/r as empirical first regimen. In adolescents, consider TDF+3TC+EFV. The preferred ARV treatment in children who failed first line regimens of 2NRTI+NNRTI (Salvage treatment) comprises 2NRTI (guided by genotype) +LPV/r, and an alternative regimen is 2NRTI (guided by genotype) +ATV/ r (use in cases with dyslipidemia who are six years or older). In cases with extensive NRTI resistance with no effective NRTI option available, double boosted PI with LPV/r+SQV or LPV/r+IDV can be considered. Consultation with an expert is recommended. Laboratory monitoring is recommended for CD4 and every six months. Viral load at least at 6 and 12 months after initiation or change of regimen, then yearly thereafter. More frequent viral load monitoring is advised for cases with unsuccessful virologic response, infants, children with imperfect adherence, or those using of third line regimens. Toxicity monitoring depends on the drug received, at least every six months, and more often as clinically indicated. These include, but are not limited to, complete blood count, renal function tests, liver function tests, urinanalysis, and lipid profiles. Therapeutic drug monitoring is recommended in cases that have ARV-related toxicity, receiving non-standard dosing or regimens, using double boosted PI, and in those with renal or hepatic impairment.

3.
Article in English | IMSEAR | ID: sea-42120

ABSTRACT

The present study evaluated the incidence and risk factors that correlated with the development of non-nucleoside reverse transcriptase inhibitor (NNRTI) related rash in 69 Thai children followed prospectively. The overall incidence of NNRTI-related rash was 16% (22% for NVP and 4% for EFV rash). The only significant predictive factor that correlated with the development of NNRTI-related rash in a multivariate logistic regression model was a CD4% decrease at week 12.


Subject(s)
Anti-HIV Agents/adverse effects , Anti-Retroviral Agents/adverse effects , CD4 Lymphocyte Count , Child , Child, Preschool , Exanthema/chemically induced , Female , HIV Reverse Transcriptase/antagonists & inhibitors , Humans , Male , Prospective Studies , Reverse Transcriptase Inhibitors/adverse effects , Risk Factors , Thailand/epidemiology
5.
Asian Pac J Allergy Immunol ; 2005 Mar; 23(1): 23-8
Article in English | IMSEAR | ID: sea-36854

ABSTRACT

HIV-infected patients may have frequent atopy caused by an imbalance of Th1 and Th2 cytokines. The objective of the present study was to investigate whether IL-2 given in addition to antiretrovirals (ARV) would result in lower IgE levels and less allergic symptoms. Patients naive to IL-2 (n=28) began IL-2 plus ARV and were followed for 12 months. IgE, eosinophil and CD4 counts, HIV RNA, symptom scoring, PFT and skin prick test (SPT) were performed. It was found that the baseline median CD4 and IgE were 386.5 cells/mm3 and 63.5 IU/ml, respectively. Four patients had allergic rhinitis (AR) and 61% had a positive SPT to at least 1 antigen. At month 12, patients had higher CD4 counts (p < 0.001) compared to the baseline; however, there were no differences in IgE levels, allergic symptom scores or HIV RNA. The eosinophil count was higher after IL-2 administration. It was concluded that IL-2 plus ARV resulted in higher CD4 counts but had no effect on atopy.


Subject(s)
Adult , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Drug Therapy, Combination , Female , HIV , HIV Infections/complications , Humans , Immunoglobulin E/blood , Interleukin-2/therapeutic use , Male , RNA, Viral/blood , Rhinitis, Allergic, Perennial/drug therapy
6.
Asian Pac J Allergy Immunol ; 2004 Jun-Sep; 22(2-3): 165-9
Article in English | IMSEAR | ID: sea-36896

ABSTRACT

We report a 7-year HIV-1 clade A/E-infected child untreated with antiretroviral therapy who had positive HIV antibody testing but undetectable plasma HIV-1 RNA by Roche Amplicor version 1.5 and bDNA version 3.0. DNA PCR was positive by methods using gag/pol primers but not env/pol primers. The patient had strong HIV-1-specific cytotoxic T lymphocyte responses, which likely contributed to her low viral burden and undetectable plasma HIV-1 RNA.


Subject(s)
Anti-Retroviral Agents , Blotting, Western , Child , DNA Primers , DNA, Viral/blood , Enzyme-Linked Immunosorbent Assay , Female , Fusion Proteins, gag-pol/blood , HIV Infections/blood , HIV-1/genetics , Humans , Interferon-gamma/blood , Polymerase Chain Reaction , RNA, Viral/blood , Viral Load
SELECTION OF CITATIONS
SEARCH DETAIL